Mabion
  • Company
    • About us
      • History
      • Leaderships
      • Team
      • EU grants
      • Requests for Proposal
      • Sustainability – ESG
      • Bussines strategy
      • Quality policy
      • Virtual Tour
    • Investors
      • Corporate documents
      • Shareholders and shares
      • Periodic reports
      • Current reports
      • Sustainability reports
      • Corporate governance at Mabion
      • Financial data
      • For Investors
      • Calendar
  • Resources
    • Science Hub
    • Press releases
    • News
    • Events
    • Media kit
  • Services
    • Process Development
    • Analytics 
    • Drug Substance Manufacturing
  • Contact
    • Contact form
    • Contact for investors
    • Contact for media
    • Careers
  • Science News
  • Resources

Biosimilars

protein characterization techniques

Protein Characterization Techniques for Biologics Development

Analytics, Biosimilars, Drug development, Proteins
end-to-end manufacturing of biosimilars

End-to-End Manufacturing of Biosimilars – From Cell Line to Commercial Product 

Biosimilars, Manufacturing

The New Era of Biosimilar Development: Seizing the Opportunity Under EMA’s Streamlined Guidelines

Biosimilars, Clinical trials, Drug development, EMA, FDA, Mabion, Regulatory
CDMO analytical expertise

Does Your CDMO Have An Analytical Edge?

Analytics, Biosimilars, Mabion

Contact

Find out how we may support your business.

bd@mabion.eu

Mabion

gen. Mariana Langiewicza 60
95-050 Konstantynów Łódzki
Poland

+48 42 207 78 90

    Mabion
    • Privacy policy
    • CDMO
    • Media kit
    • Press releases
    • Events

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. HTML Sitemap

    Powered by

    Veneo